Skip to main content

Table 4 Indirect comparison of objective response rate

From: Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

RR of ORR (95% CI)
 0.21 (0.11–0.40) * GEM-NAB   
 0.25 (0.13–0.49) * 1.22 (0.95–1.58) FOLFIRINOX  
 0.30 (0.15–0.60) * 1.43 (1.04–1.96) * 1.17 (0.87–1.56) mFOLFIRINOX
  1. Abbreviation: HR: hazard ratio; ORR: objective response rate; CI: confidence interval; GEM: gemcitabine; GEM-NAB: Gemcitabine plus nab-paclitaxel; FOLFIRINOX: the combination of 5-fluorouracil, oxaliplatin, and irinotecan; mFOLFIRINOX: at least one of the drugs was reduced and/or the removal of 5-FU bolus in FOLFIRINOX
  2. Notes: Comparisons between treatments were read from left to right, and the estimate (risk ratio, RR) with 95% confidence interval for a given comparison was read in the intersection of two treatments. The value of estimates higher than 1 indicated that column-defining treatment had better efficacy
  3. * Denotes p-value < 0.05